Capricor Therapeutics, Inc.
CAPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $22 | $25 | $3 | $0 |
| % Growth | -11.5% | 886.8% | 941.8% | – |
| Cost of Goods Sold | $50 | $36 | $22 | $0 |
| Gross Profit | -$28 | -$11 | -$19 | $0 |
| % Margin | -124.4% | -44.8% | -755.1% | 100% |
| R&D Expenses | $50 | $36 | $22 | $14 |
| G&A Expenses | $15 | $13 | $10 | $8 |
| SG&A Expenses | $15 | $13 | $10 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$50 | -$36 | -$22 | $0 |
| Operating Expenses | $15 | $13 | $10 | $21 |
| Operating Income | -$43 | -$24 | -$30 | -$21 |
| % Margin | -191.1% | -95.6% | -1,163.9% | -8,549.9% |
| Other Income/Exp. Net | $2 | $2 | $1 | $1 |
| Pre-Tax Income | -$40 | -$22 | -$29 | -$20 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$40 | -$22 | -$29 | -$20 |
| % Margin | -181.7% | -88.5% | -1,137.4% | -8,175.9% |
| EPS | -1.15 | -0.83 | -1.18 | -0.87 |
| % Growth | -38.6% | 29.7% | -35.6% | – |
| EPS Diluted | -1.15 | -0.83 | -1.18 | -0.87 |
| Weighted Avg Shares Out | 35 | 27 | 25 | 23 |
| Weighted Avg Shares Out Dil | 35 | 27 | 25 | 23 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$41 | -$23 | -$29 | -$21 |
| % Margin | -184.7% | -91.4% | -1,143% | -8,449.5% |